SCHEMBL7203420

SCHEMBL7203420

O=c1cc(NCc2cccnc2)c2ccccc2n1-c1nc2ccccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 2/20 0.48
HTT P42858 2/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
AURKA O14965 3/20 0.46
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
PDE5A O76074 2/20 0.41
POLB P06746 1/20 0.41
PDE9A O76083 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7206567 0.74 ACP1 (0.52) ALDH1A1KDM4EAURKAGAACYP1A2
SCHEMBL7202162 0.73 AURKA (0.45) AURKA
SCHEMBL7204767 0.73 JAK1 (0.56) KDM4EHTTSMN1; SMN2AURKAKMT2A
SCHEMBL5308810 0.73 AURKA (0.62) ALDH1A1KDM4EHTTNPC1RAB9A
SCHEMBL7203775 0.72 JAK1 (0.49) AURKA
SCHEMBL7200373 0.72 ACP1 (0.55) ALDH1A1KDM4EHTTNPC1HPGD
SCHEMBL7201841 0.71 AURKA (0.43) ALDH1A1KDM4EHTTSMN1; SMN2AURKA
SCHEMBL7199711 0.69 JAK1 (0.52) AURKA
SCHEMBL20040367 0.69 AURKA (0.69) ALDH1A1KDM4EHTTNPC1HPGD
SCHEMBL14796713 0.69 FGFR1 (0.60) ALDH1A1KDM4EHTTNPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 US disclosed